BK-5Cl-NM-AMT

BK-5Cl-NM-AMT

Clinical data
Other names	βk-5Cl-NM-αMT; β-Keto-5-chloro-N-methyl-αMT; β-Keto-5-chloro-N-methyl-AMT; α,N-Dimethyl-5-chloro-β-ketotryptamine; β-Oxo-5-chloro-α-methyl-NMT
Drug class	Monoamine releasing agent
Identifiers
IUPAC name 1-(5-chloro-1H-indol-3-yl)-2-(methylamino)propan-1-one
CAS Number	2764945-61-9 Y
PubChem CID	162765502
Chemical and physical data
Formula	C12H13ClN2O
Molar mass	236.70 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C(=O)C1=CNC2=C1C=C(C=C2)Cl)NC
InChI InChI=1S/C12H13ClN2O/c1-7(14-2)12(16)10-6-15-11-4-3-8(13)5-9(10)11/h3-7,14-15H,1-2H3 Key:JNYZOLQTXCZJRL-UHFFFAOYSA-N

BK-5Cl-NM-AMT, or βk-5Cl-NM-αMT, also known as β-keto-5-chloro-N-methyl-αMT or α,N-dimethyl-5-chloro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.

It is known to induce the release of serotonin and dopamine, with respective EC₅₀Tooltip half-maximal effective concentration values of 200 nM and 865 nM in rat brain synaptosomes, whereas norepinephrine release was not reported. In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT₁, 5-HT₂, and 5-HT₃ receptors. In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).

BK-5Cl-NM-AMT was first described in the literature by 2023. It was patented by Matthew Baggott and Tactogen as a potential novel entactogen. BK-5Cl-NM-AMT is the 5-chloro derivative of BK-NM-AMT. Other analogues of the drug include BK-5F-NM-AMT and BK-5Br-NM-AMT.

See also

• 5-Chloro-AMT

External links

• β-Oxo-5-chloro-α-methyl-NMT (BK-5Cl-NM-AMT) - Isomer Design